Immunovia Publ Financials
| IMMNOV Stock | SEK 0.85 0.20 30.77% |
Immunovia |
Understanding current and past Immunovia Publ Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immunovia Publ's financial statements are interrelated, with each one affecting the others. For example, an increase in Immunovia Publ's assets may result in an increase in income on the income statement.
Please note, the presentation of Immunovia Publ's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunovia Publ's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Immunovia Publ's management manipulating its earnings.
Immunovia Publ Stock Summary
Immunovia Publ competes with ADDvise Group, Hanza AB, Awardit AB, Doxa AB, and Advenica. Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0006091997 |
| Business Address | Medicon Village, Lund, |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Benchmark | Dow Jones Industrial |
| Website | www.immunovia.com |
| Phone | 46 4 62 75 60 00 |
| Currency | SEK - Swedish Kronor |
You should never invest in Immunovia Publ without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Immunovia Stock, because this is throwing your money away. Analyzing the key information contained in Immunovia Publ's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Immunovia Publ Key Financial Ratios
Immunovia Publ's financial ratios allow both analysts and investors to convert raw data from Immunovia Publ's financial statements into concise, actionable information that can be used to evaluate the performance of Immunovia Publ over time and compare it to other companies across industries.| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Target Price | 110.0 | |||
| Number Of Employees | 64 | |||
| Beta | 1.29 |
Immunovia Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunovia Publ's current stock value. Our valuation model uses many indicators to compare Immunovia Publ value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunovia Publ competition to find correlations between indicators driving Immunovia Publ's intrinsic value. More Info.Immunovia publ AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunovia Publ by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunovia Publ's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Immunovia publ AB Systematic Risk
Immunovia Publ's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immunovia Publ volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Immunovia publ AB correlated with the market. If Beta is less than 0 Immunovia Publ generally moves in the opposite direction as compared to the market. If Immunovia Publ Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immunovia publ AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immunovia Publ is generally in the same direction as the market. If Beta > 1 Immunovia Publ moves generally in the same direction as, but more than the movement of the benchmark.
Immunovia Publ November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Immunovia Publ help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunovia publ AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunovia publ AB based on widely used predictive technical indicators. In general, we focus on analyzing Immunovia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunovia Publ's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.91 | |||
| Information Ratio | 0.0281 | |||
| Maximum Drawdown | 80.75 | |||
| Value At Risk | (6.56) | |||
| Potential Upside | 7.81 |
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |